SLC is targeting high barrier non-penem drug candidates. These non-penem products will leverage SLC's expertise in sterile crystallization and the aseptic processing of sterile powder. Eventual manufacturing will occur in Chunan, Taiwan.

Our pipeline includes but is not limited to:
Generic Brand Route Indications
Leuprolide acetate Lupron Injection Prostate Cancer Endometriosis Uterine Leiomyoma
Teriparatide Forteo Subcutaneous Osteoporosis
Liraglutide Victoza Subcutaneous Type-2 Diabetes Mellitus
Exenatide Byetta Subcutaneous Type-2 Diabetes Mellitus